INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
CR
Corporate insider

Chambers Rebecca

Chief Financial OfficerCIK 0001823563

EDGAR filingsOpen in network
Disclosed transactions12
Buys / sells0 / 7
Max Insider Score26
Connections with evidence2

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$162K
3,603 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Alamar Biosciences, Inc.Director · Apr 20, 2026
  • Insider ofevidence
    VERACYTE, INC.Chief Financial Officer · Nov 7, 2025
9
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL
$106K
2,477 sh
Sep 4, 2026
Sep 4, 2026
traded Sep 4, 2026
+0d
SEC FORM 4

Evidence

9
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$51K
1,175 sh
Sep 4, 2026Sep 4, 2026
traded Sep 4, 2026
+0dSEC FORM 4

Evidence

14
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$79K
1,600 sh
Jun 4, 2026Jun 4, 2026
traded Jun 4, 2026
+0dSEC FORM 4

Evidence

0
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$177K
3,693 sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

14
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$98K
1,961 sh
Jun 4, 2026Jun 4, 2026
traded Jun 4, 2026
+0dSEC FORM 4

Evidence

12
CR
Chambers RebeccaDirector
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
140.6K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
CR
Chambers RebeccaDirector
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
140.6K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

19
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$224K
4,741 sh
Dec 4, 2025Dec 4, 2025
traded Dec 4, 2025
+0dSEC FORM 4

Evidence

0
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$156K
3,384 sh
Dec 2, 2025Dec 4, 2025
traded Dec 2, 2025
+2dSEC FORM 4

Evidence

26
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$398K
8,537 sh
Dec 4, 2025Dec 4, 2025
traded Dec 4, 2025
+0dSEC FORM 4

Evidence

20
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$287K
7,000 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence